PhD Scientific Days 2022

Pathology and Oncology III. (Poster discussion will take place in the Aula during the Coffee Break)

Investigation of miRNA Expression Patterns in Follicular Lymphoma Patients with Different Disease Outcomes

Előadó neve

Dr. Nagy, Ákos

Előadó munkahelye

Department of Pathology and Experimental Cancer Research, Semmelweis University

Előadó telefonszáma

+36305310236

Előadó e-mail címe

nagy.akos1@med.semmelweis-univ.hu

Az előadás címe

Investigation of miRNA Expression Patterns in Follicular Lymphoma Patients with Different Disease Outcomes

Szerző(k) neve és munkahelye

Ákos Nagy1, Bence Bátai1, Laura Kiss1, Gábor Mikala2, Péter Attila Király3, Tamás Schneider3, András Masszi3, Ádám Jóna4, Csaba Bödör1

1 HCEMM-SE Molecular Oncohematology Research Group, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
2 National Institute of Hematology and Infectious Diseases, Central Hospital of Southern Pest, Budapest, Hungary
3 National Institute of Oncology, Budapest, Hungary
4 Hematology Division, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary

Bemutatás módja

Poszter

Szekció

Pathology and Oncology III. (Poster discussion will take place in the Aula during the Coffee Break)

Language of the presentation

Hungarian

Preferred session

Pathology and Oncology

Összefoglaló szövege

INTRODUCTION: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lympoma, with an overall survival of 15 years. Although, the disease has an indolent biology, FL is characterized by a remitting, relapsing clinical course with the occurrence of high-grade transformation to a more aggressive lymphoma in around 20% of patients. Accurate patient prognostication at diagnosis is ineffective with current clinical indexes and histological methods. Recently, several attempts have been made to determine prognosis from diagnostic tissue samples at the molecular level (DNA, mRNA), but none could demonstrate clinical robustness. To date, only limited data is available of miRNA expression with regards to risk stratification in FL.

AIMS: In this study we aimed to investigate miRNA expression patterns in FL patients with poor and excellent outcome.

METHODS: We collected 40 diagnostic tissue samples from FL patients. Twenty-two patients had an excellent outcome (>10 years in remission, cured FL group: crFL) following first line immunochemotherapy (ICT), meanwhile eighteen patients transformed to aggressive lymphoma (trFL group) within five years after first line ICT. We isolated RNA from the diagnostic formalin fixed paraffin embedded samples, then we analyzed the expression of 798 miRNA genes with the nCounter NanoString platform (NanoString, USA). miRNA expression patterns were analyzed and visualized with the Rosalind webtool (Rosalind, USA).

RESULT: After normalization of miRNA expression counts to house-keeping controls, we detected 3-fold downregulation (p<0.05) of five miRNAs (miR-769-3p, miR-656-3p, miR-494-3p, miR-575, miR-630) in the crFL group compared to the trFL group. None of the investigated miRNAs were selectively upregulated in the trFL group.

CONCLUSION: In this study we describe five miRNAs, whose downregulation in the diagnostic tissue samples indicate excellent prognosis following ICT. Future studies are needed to elaborate the functional role of these miRNAs in FL.

Funding: NKFIH KDP-1022882, EFOP-3.6.3-VEKOP-16-2017-00009, ÚNKP-21-3, H2020-739593, K21_137948, TKP2021-EGA-24, TKP2021-NVA-15 and Elixir Hungary.

University and Doctoral School

Semmelweis University, Doctoral School of Pathological Sciences

Supervisor

Dr. Csaba Bödör

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

4675

Start

10:50

End

10:55

Authors (legacy)

Ákos Nagy1, Bence Bátai1, Laura Kiss1, Gábor Mikala2, Péter Attila Király3, Tamás Schneider3, András Masszi3, Ádám Jóna4, Csaba Bödör1

1 HCEMM-SE Molecular Oncohematology Research Group, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
2 National Institute of Hematology and Infectious Diseases, Central Hospital of Southern Pest, Budapest, Hungary
3 National Institute of Oncology, Budapest, Hungary
4 Hematology Division, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary